Reactions 1871, p352 - 4 Sep 2021
Piperacillin/tazobactam
SEosinophilic-pneumonia: case report
In a clinical chart review and post-mortem examination from a retrospective monocentric study (COVIDAge study) involving 264 patients aged 75 years and older and hospitalized [Switzerland] in acute care and positive for SARS-CoV-2, a 75-year-old man was described, who developed eosinophilic pneumonia during treatment with piperacillin/tazobactam [routes and dosages not stated].
The man had medical history of COVID-19, arterial hypertension, ischaemic heart disease, stroke, arteriosclerosis, dementia, IgA neuropathy, chronic kidney failure and cirrhosis. He started receiving treatment with piperacillin/tazobactum. his hospital course was complicated with acute renal failure, liver cholestases, anaemia, suspicion of bacterial pneumonia and unexplicated persisting inflammation. Consequently, he died of suspected hypoxaemic respiratory failure associated with Covid-19. However, an autopsy revealed the cause of death as hypoxaemic respiratory failure associated with Covid-19 and eosinophilic pneumonia.
Malezieux-Picard A, et al. Undetected causes of death in hospitalized elderly with covid-19: Lessons from autopsy. Journal of Clinical Medicine 10: 1337, No. 7, Apr 2021.
Available from: URL: http://doi.org/10.3390/jcm10071337 803591914
1
Reactions 4 Sep 2021 No. 1871 0114-9954/21/1871-0001/$14.95 Adis © 2021 Springer Nature Switzerland AG. All rights reserved
